CSIMarket
 


Emergent Biosolutions Inc   (EBS)
Other Ticker:  
 

Cumulative Emergent Biosolutions Inc 's Working Capital Ratio for Trailing Twelve Months Period

EBS's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

EBS Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth -47 % 147.39 % 150.52 % 387.84 % 228.76 %
Y / Y Current Assets Growth -43.86 % -35.56 % -28.27 % 11 % -4.85 %
Working Capital Ratio for Trailing Twelve Months Period 1.05 1.03 1.27 1.55 2.23
Total Ranking # 1843 # 2945 # 2770 # 2535 # 2148
Seq. Current Liabilities Growth -1.91 % -4.21 % -42.98 % -1.07 % 357.86 %
Seq. Current Assets Growth -5.73 % -7.32 % -36.32 % 0.9 % 8.22 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Current Liabilities decreased faster than Emergent Biosolutions Inc 's average Current Assets, this led to increase in in Emergent Biosolutions Inc 's Working Capital Ratio for Trailing Twelve Months Period to 1.05, Working Capital Ratio for Trailing Twelve Months Period remained below Emergent Biosolutions Inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 192 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Emergent Biosolutions Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about EBS
Working Capital Ratio EBS in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 193
Sector # 428
S&P 500 # 1848


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
6.45 3.98 1.03
(Dec 31 2017)   (Sep 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Amphastar Pharmaceuticals Inc   2.90 
Kamada Ltd   2.89 
Amicus Therapeutics inc   2.88 
Omeros Corp  2.87 
Nucana Plc  2.84 
Immunoprecise Antibodies Ltd   2.84 
Entrada Therapeutics Inc   2.83 
Evotec Se  2.81 
Kiora Pharmaceuticals Inc  2.81 
Mustang Bio inc   2.78 
Nls Pharmaceutics Ltd   2.75 
Prestige Consumer Healthcare Inc   2.74 
Clever Leaves Holdings Inc   2.71 
Acadia Pharmaceuticals Inc   2.70 
Rvl Pharmaceuticals Plc  2.70 
Intercept Pharmaceuticals inc   2.68 
Universe Pharmaceuticals Inc  2.68 
Hutchmed china Limited  2.64 
Perrigo Company Plc  2.64 
Biovie Inc   2.62 
23andme Holding Co  2.59 
Vaxxinity Inc   2.56 
Mallinckrodt Plc  2.56 
Spectrum Pharmaceuticals Inc   2.53 
Societal Cdmo Inc   2.52 
Mannkind Corporation  2.52 
Mereo Biopharma Group Plc  2.52 
Revelation Biosciences Inc   2.50 
Alkermes Plc   2.48 
Biodexa Pharmaceuticals Plc  2.47 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com